BioStock: DanCann Pharma towards commercialisation with rights issue

For DanCann, the aim is clear – to give patients who lack treatment options a better life through medical cannabis and cannabinoids. After building a solid portfolio of products, the next step for the Danish pharma company is commercialisation. In order to take this step, the company is now conducting a rights issue that, if fully subscribed, can raise 28.5 million DKK. BioStock talked to CEO Jeppe Krog Rasmussen to find out more.

Read the full interview with Jeppe Krog Rasmussen at biostock.se:

https://www.biostock.se/en/2022/10/dancann-pharma-towards-commercialisation-with-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/